The Risk of Venous Thromboembolism in Atopic Dermatitis: A Population-Based Cohort Study

Atopic Dermatitis

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Kridin S, Mayer E, Sawaed W, Ludwig RJ

doi: 10.1111/jdv.20864

Vitiligo

Evaluating Cancer Risk in a Large Cohort of 25,008 Vitiligo Patients: Insights from a Comprehensive Cohort Population-Based Study

J Am Acad Dermatol

Schonmann Y, Cohen NT, Czarnowicki T

doi: 10.1016/j.jaad.2024.11.043

Systemic Lupus Erythematosus

Venous thromboembolism in patients with lupus nephritis: frequency and risk factors-a cohort study

Rheumatology (Oxford)

Kharouf F, Mehta P, Li Q, Gladman DD, Whittall Garcia LP, Touma Z

doi: 10.1093/rheumatology/keaf464

Atopic Dermatitis

Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study

J Am Acad Dermatol

Chen TL, Ma SH, Ou WF, Chen CC, Wu CY

doi: 10.1016/j.jaad.2025.08.020

Autoimmune Disease

Primary Cesarean delivery and future risk of maternal autoimmune disease: A population-based cohort study

J Autoimmun

Scime NV, Grandi SM, De Vera MA, Dennis CL, Boblitz A, Brown HK

doi: 10.1016/j.jaut.2025.103370

Atopic Dermatitis

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

J Eur Acad Dermatol Venereol

Kridin K, Abdelghaffar M, Bieber K, Thaci D, Ludwig RJ

doi: 10.1111/jdv.20724

Psoriasis

Psoriasis and the risk of 26 cancers: pooled population-based cohort studies from Denmark, England, Israel, and Taiwan

Br J Dermatol

Trafford AM, Schonmann Y, Chen TC, Egeberg A, Parisi R, Kontopantelis E, Wang TC, Rutter MK, Chen LC, van Staa T, Lee MS, Kridin K, Cohen AD, Chan KA, Wright AK, Griffiths CEM, Ashcroft DM

doi: 10.1093/bjd/ljaf399

Psoriatic Arthritis

Increased risk of psoriatic arthritis in patients with familial Mediterranean fever: a population-based cohort study

Rheumatology (Oxford)

Haddad A, Slutsker B, Stein N, Gazitt T, Feldhamer I, Cohen A, Saliba W, Zisman D

doi: 10.1093/rheumatology/keaf607

Osteoporosis

Long Dosing Intervals of Parenteral Antiosteoporosis Medications and the Decrease in Societal Fracture Risk: A 11-Year Nationwide Population-Based Cohort Study

Mayo Clin Proc

Fu SH, Yen HK, Yang RS, Hung CC, Lin JW, Lee MT, Chen HM, Wu CH, Hsu CC, Li CY, Groot OQ, Wang CY

doi: 10.1016/j.mayocp.2024.05.002

Related content

Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis: A global cohort study

Evaluating Cancer Risk in a Large Cohort of 25,008 Vitiligo Patients: Insights from a Comprehensive Cohort Population-Based Study

Venous thromboembolism in patients with lupus nephritis: frequency and risk factors-a cohort study

Decreased Risk of Reduced Linear Growth Among Children with Atopic Dermatitis Receiving Dupilumab: A Cohort Study

Primary Cesarean delivery and future risk of maternal autoimmune disease: A population-based cohort study

The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study

Psoriasis and the risk of 26 cancers: pooled population-based cohort studies from Denmark, England, Israel, and Taiwan

Increased risk of psoriatic arthritis in patients with familial Mediterranean fever: a population-based cohort study

Long Dosing Intervals of Parenteral Antiosteoporosis Medications and the Decrease in Societal Fracture Risk: A 11-Year Nationwide Population-Based Cohort Study